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Objectives: An additive genetic risk score (GRS) for
coronary heart disease (CHD) has previously been
associated with incident CHD in the population-based
Greek European Prospective Investigation into Cancer
and nutrition (EPIC) cohort. In this study, we explore
GRS-‘environment’ joint actions on CHD for several
conventional cardiovascular risk factors (ConvRFs),
including smoking, hypertension, type-2 diabetes
mellitus (T2DM), body mass index (BMI), physical
activity and adherence to the Mediterranean diet.
Design: A case–control study.
Setting: The general Greek population of the EPIC study.
Participants and outcome measures: 477 patients
with medically confirmed incident CHD and 1271
controls participated in this study. We estimated the
ORs for CHD by dividing participants at higher or lower
GRS and, alternatively, at higher or lower ConvRF, and
calculated the relative excess risk due to interaction
(RERI) as a measure of deviation from additivity.
Results: The joint presence of higher GRS and higher
risk ConvRF was in all instances associated with an
increased risk of CHD, compared with the joint presence
of lower GRS and lower risk ConvRF. The OR (95% CI)
was 1.7 (1.2 to 2.4) for smoking, 2.7 (1.9 to 3.8) for
hypertension, 4.1 (2.8 to 6.1) for T2DM, 1.9 (1.4 to 2.5)
for lower physical activity, 2.0 (1.3 to 3.2) for high BMI
and 1.5 (1.1 to 2.1) for poor adherence to the
Mediterranean diet. In all instances, RERI values were
fairly small and not statistically significant, suggesting
that the GRS and the ConvRFs do not have effects
beyond additivity.
Conclusions: Genetic predisposition to CHD,
operationalised through a multilocus GRS, and ConvRFs
have essentially additive effects on CHD risk.
INTRODUCTION
Coronary heart disease (CHD) is a leading
cause of death and disability worldwide.
1
Lifestyle and environmental factors, such as
cigarette smoking, physical inactivity, chrono-
disruption and unhealthy diets, play a signiﬁ-
cant role in its development and are largely
responsible for increased risk of this
disease.
23In addition, compelling evidence
from the literature suggest a genetic basis for
CHD
4 so that genetic data may identify indi-
viduals who have an inherited predisposition
to develop CHD.
During the past few years, genome-wide
association studies (GWAS) have successfully
identiﬁed a large number of chromosomal
loci and genetic variants that are robustly
associated with CHD,
5–11 although their
effects on risk are generally fairly small. To
combine the relatively small effects of indi-
vidual genes and to better capture the
complex relationship between genetics and
CHD, genotypes at multiple genetic variants
have previously been combined into scores
calculated according to the number of risk
alleles carried.
12 13 To date, several studies
have examined the utility of different genetic
risk scores (GRSs) to identify participants
at increased CHD risk.
14–18 Ripatti et al
16
Strengths and limitations of this study
▪ Strengths of the study are the population-based
prospective cohort design of the underlying
study and the minimal concern for population
stratification.
▪ Another strength is the use of a multilocus
genetic risk score using SNPs with documented
association with CHD.
▪ The main limitation of this study stems from the
modest numbers of incident CHD cases, not
withstanding the fact that the underlying cohort
was large and was followed for approximately
10 years.
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from GWAS for myocardial infarction or CHD was asso-
ciated with risk of CHD, and that the upper quintile of
individuals of European ancestry who carried the most
risk alleles had a roughly 1.7 times increased risk of
CHD when compared with those in the lowest quintile
of GRS. Using a similar approach, we have shown that a
GRS based on nine documented genetic variants from
GWAS is associated with incident CHD in the
population-based Greek European Prospective
Investigation into Cancer and nutrition (EPIC) cohort.
19
Despite the success of GWAS in identifying novel
genetic contributors to CHD, the heritability of
common disorders cannot be adequately explained by
the genes that have been discovered; moreover, for the
most part, we do not know how these recently discovered
loci interact with the environment and what role such
interactions play in the development of the disease.
20 21
Testing such interactions is thus a new frontier for
large-scale GWAS of CHD,
22 and some initial ﬁndings
support the important role of environmental exposures
in inﬂuencing the magnitude of the genetic associations
with cardiovascular disease
23 or other common diseases
and traits.
24 25
The aim of the current study was to explore potential
GRS-‘environment’ interaction effects on CHD for
several important conventional cardiovascular risk
factors (ConvRFs), including smoking, hypertension,
type-2 diabetes mellitus (T2DM), body mass index
(BMI), physical activity and adherence to the
Mediterranean diet (MedDiet). We have used resources
generated in the Greek-EPIC cohort in which medically
documented incident cases of CHD
26 are recorded




The EPIC is a longitudinal study aimed at investigating
the role of biological, nutritional, lifestyle and environ-
mental factors in the aetiology of cancer and other
chronic diseases. The study has been described in detail
elsewhere.
27 28 The recruitment of Greek-EPIC partici-
pants was from 1994 to 1999. The active follow-up of
study participants is repeated every 2–4 years. In each
round, the focus of follow-up is on the update of infor-
mation related to health status of the participants. For
this analysis, exposure data at enrolment and follow-up
data until the end of 2009 for outcomes are considered.
By December 2009, 788 participants were diagnosed
with an incident, medically conﬁrmed, CHD or stroke
event and were considered eligible for a study also evalu-
ating genetic predisposition.
19 For each case, an attempt
was made to choose two control participants matched
for sex, age (±2 years) and date of recruitment
(±6 months). Both cases and controls were free of CHD
and stroke at baseline; the ﬁnal study sample consisted
of 788 cases (494 CHD, 320 stroke, 26 both diseases)
and 1345 controls. For each study participant, a buffy
coat sample was drawn from the Greek-EPIC
bio-repository and genomic DNA was extracted. CHD
events included myocardial infarction, angina and other
ischaemic heart disease (cardiac arrest, presence of
cardiac and vascular implants and grafts), with several
cases following in more than one categories.
26 28 All pro-
cedures were in accordance with the Helsinki
Declaration and all participants provided written
informed consent.
Selection of genetic variants, genotyping and GRS
calculation
We constructed a multilocus GRS by using nine previ-
ously reported genetic variants associated with myocar-
dial infarction or CHD from GWAS, with convincing
replication evidence in populations with European
ancestry,
61 01 62 93 0as previously described.
19 The var-
iants used were: rs11206510 at 1p32 near PCSK9,
rs646776 at 1p13 near CELSR2-PSRC1-SORT1,
rs17465637 at 1q41 in MIA3, rs6725887 at 2q33 in
WDR12, rs9349379 at 6p24 in PHACTR1, rs1746048 at
10q11 near CXCL12, rs1122608 at 19p13 near LDLR,
rs9982601 at 21q22 near SLC5A3-MRPS6-KCNE2 and the
lead variant (rs1333049) at locus 9p21 near CDKN2A/2B
identiﬁed by the Wellcome Trust Case Control
Consortium.
7
Genotyping was performed blindly as to case–control
status with the TaqMan allelic discrimination system on
the ABI 7900HT platform using custom genotyping
assays and probes designed by Applied Biosystems, Inc
(Foster City, California, USA). Replicate quality control
samples yielded 100% concordance and call rates
exceeded 98%. All genotypes were analysed in the
Nutrition and Genomics Laboratory, Jean Mayer US
Department of Agriculture, Human Nutrition Research
Center on Aging at Tufts University, Boston,
Massachusetts, USA.
A GRS was computed for each individual as the sum
of the number of risk alleles across all nine variants,
after weighting each one by its estimated effect size in
the discovery samples
51 0as generally used
16–18 and pre-
viously described.
19 In this study, the minimum and
maximum weighted GRS values were, respectively, 4.6
and 17.7 in control participants and 5.7 and 18.8 in
CHD cases.
Conventional risk factors for CHD
We evaluated GRS-‘environment’ interaction effects on
CHD for several important conventional ConvRFs for
which information was collected at enrolment. These
factors were: smoking status, hypertension, T2DM, BMI,
waist-to-hip ratio, physical activity, energy intake and
adherence to the MedDiet. Participants were charac-
terised as current, former or never smokers and were
considered as hypertensive if they met one of the follow-
ing criteria: (1) their measured arterial blood pressure
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higher diastolic and (2) self-reported intake of an anti-
hypertensive treatment. T2DM was identiﬁed through
self-reported T2DM-spesiﬁc medication use or self-
reported medical diagnosis of T2DM. Weight, height,
waist and hip circumference were measured using stand-
ard procedures, and BMI was calculated in kg/m
2. With
respect to physical activity, we used a metabolic equiva-
lent index (MET-value) that expresses the amount of
energy per kilogram of body weight expended during
an average day.
31 Dietary information of the participants
was measured at baseline using a validated interviewer-
administered food frequency questionnaire (FFQ).
32
The frequency of consumption of about 200 foods and
recipes that are common in Greece was reﬂected at the
FFQ. The daily energy intake was assessed by recording
participants’ energy intake (in kcal). Adherence to the
MedDiet was assessed with a MedDiet score that incorpo-
rates the salient characteristics of this diet, that is, high
intake of plant foods and olive oil, low intake of meat
and dairy products and moderate intake of alcohol. This
score, with values from 0 to 9 (higher scores indicate
greater adherence to the MedDiet), is associated with
death from CHD, with lower values predicting higher
incidence of death from CHD.
28 33
Statistical analysis
For this study, we have used all incident CHD cases and
all available control participants and we have proceeded
through unconditional logistic regression.
Mean values of quantitative characteristics, as well as
percentages for qualitative ones, by sex and case–control
status, were calculated for descriptive purposes. We eval-
uated whether CHD incidence is related to the afore-
mentioned ConvRFs using logistic regression, adjusting
for age, sex and GRS. We evaluated ORs for CHD, as
estimates of the incidence rate ratios, in relation to age,
sex and higher or lower risk with respect to GRS (above
or equal to vs below the sex-speciﬁc median score in
controls) and, alternatively, on the basis of smoking
status (current vs never/former smoker), hypertension
(yes vs no), T2DM (yes vs no), physical activity (below vs
above or equal to the sex-speciﬁc median), energy
intake (below vs above or equal to the sex-speciﬁc
median), MedDiet score (below vs above or equal to the
median score of 4.0), BMI (above or equal vs below
25 kg/m
2) or waist-to-hip ratio (above or equal to vs
below the sex-speciﬁc median).
In order to access the nature of the joint effects of
GRS and ConvRFs, we calculated the relative excess risk
due to interaction (RERI), as deﬁned by Rothman.
34
RERI is an estimate of excess or deﬁcit risk that is attrib-
utable to the interaction between two exposures, in this
case GRS and each one of the ConvRFs; it measures
deviation from additivity of effects independently of the
risk scale of the outcome. From the ORs of the logistic
regression, we computed the RERIs between GRS and
ConRFs as follows
35; let X+ and Y+ denote the presence
of the risk factors X (GRS in our analysis) and Y (con-
ventional factor) and X– and Y– denote the absence of
these risk factors. Then, by considering that the OR esti-
mates the relative risk (RR) we have that
RERI(X;Y)¼ (RRXþYþ   RRX Y )
  (RRXþY    RRX Y )
  (RRX Yþ   RRX Y )
that is, RERI(X,Y)=(ORX+Y+−1)−(ORX+Y–−1)−(ORX–Y+−1)
The necessary variance estimators of RERI for the con-
struction of 95% CIs were derived using the standard δ
method.
35 All statistical analyses were conducted using
the Stata Statistical Software, release V.11 (StataCorp
2009, StataCorp LP).
RESULTS
Of the 1839 study participants with genotype data (494
patients with incident CHD only and 1345 controls), 91
participants had missing data for one or more of the
ConvRFs; thus, our analyses were restricted to 477 CHD
cases and 1271 controls with complete datasets. The
characteristics of the study participants at enrolment
according to sex and case–control status are given in
table 1.
The association of ConvRFs with CHD incidence in
this prospective cohort study is illustrated in table 2.A s
expected, smoking, hypertension, T2DM and an
increased BMI and waist-to-hip ratio were all associated
with a substantial increase in the risk of CHD, whereas
higher levels of physical activity and energy expenditure
(as reﬂected in an increased energy intake)
36 were asso-
ciated with a decrease in risk. Greater adherence to the
MedDiet was also associated with an 11% decreased risk
of CHD, although this association was not statistically
signiﬁcant.
We then examined the impact on CHD risk of the
joint presence of genetic predisposition and ConvRFs by
modelling the data through unconditional logistic
regression, adjusting for age and sex. Speciﬁcally, we esti-
mated ORs for CHD incidence depending on partici-
pants having a higher or lower GRS and simultaneously
as being at higher or lower risk on the basis of a conven-
tional risk factor. Table 3 gives the distribution of CHD
cases and controls by GRS and each ConvRF (lower vs
higher risk for CHD) in men and women. As shown in
table 4, in all instances the joint presence of higher GRS
and higher-risk ConvRF is associated with a substantial
increase in the risk of CHD, compared with the joint
presence of lower GRS and lower-risk ConvRF. In add-
ition, participants with higher GRS values (high-risk
genetic predisposition) and simultaneously at higher
risk because of a ConvRF are characterised by an OR for
CHD that is higher than the OR among individuals with
high-risk genetic predisposition who belong to the lower
risk category of the respective ConvRF (smoking status,
OR 1.70 vs 1.49; hypertension, OR 2.72 vs 1.21; T2DM,
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intake, OR 1.75 vs 1.43; MedDiet score, OR 1.51 vs 1.24;
BMI, OR 2.01 vs 1.47; waist-to-hip ratio, OR 1.88 vs
1.25).
Relative excess risks due to interaction (RERIs)
between the GRS and each one of the ConvRFs are pre-
sented in the last column of table 4. There is some evi-
dence for superadditivity with respect to hypertension,
and, on the contrary, some evidence for subadditivity
with respect to smoking. Nevertheless, in all instances,
RERI values are fairly small and the 95% CIs cover the
null values of RERI, suggesting that the GRS and the
conventional risk factors do not have effects beyond
additivity.
DISCUSSION
In a sizable case–control study nested in the population-
based Greek-EPIC cohort, we have found that genetic
predisposition to CHD, operationalised through a
multilocus GRS (the sum of high-risk alleles in 9 genetic
variants) and ConvRFs have essentially additive inﬂuence
on CHD risk. In other words, people at high risk for
CHD because of genetic susceptibility tend to have addi-
tively increased RR when also exposed to any of the
investigated conventional risk factors. This is highlighted
by the fact that, while among people with low genetic
risk, only ﬁve of the eight investigated ConvRFs were
documentable as ‘statistically signiﬁcant’, all eight were
documentable as such among people at high genetic
risk.
Evaluation of joint effects in a multiplicative scale
through interaction terms in logistic regression and other
models that rely on similar principles are very valuable on
account of their ﬂexibility and provision of insights on
causal pathways. Additive models (and deviations from
additivity), however, as evaluated in this paper, convey
straightforward answers to questions of preventive and
clinical importance by pointing to individual change of
risk in relation to values of conventional risk factors and
Table 1 Characteristics of conventional cardiovascular risk factors and genetic risk score for incident CHD cases and
controls in the Greek-EPIC cohort
Cases (n=477) Controls (n=1271)
Men (n=331) Women (n=146) Men (n=784) Women (n=487)
Age (years) 60.1 (11.4) 66.2 (6.9) 60.6 (10.9) 65.6 (7.3)
Body mass index (kg/m
2) 28.7 (3.8) 31.1 (5.5) 28.0 (3.9) 29.8 (4.9)
Waist-to-hip ratio 0.97 (0.06) 0.87 (0.07) 0.96 (0.07) 0.85 (0.09)
Physical activity (MET-h/day) 33.8 (5.6) 33.6 (3.7) 34.7 (6.0) 34.5 (4.5)
Energy intake (kJ) 9250.8 (3000.8) 6733.7 (2021.7) 9370.9 (2700.4) 7028.7 (2330.5)
MedDiet score * 4.4 (1.7) 4.1 (1.6) 4.4 (1.7) 4.2 (1.6)
Hypertensive, n (%)† 224 (67.7) 131 (89.7) 452 (57.7) 318 (65.3)
Type 2 diabetes, n (%)‡ 68 (20.5) 51 (34.9) 66 (8.4) 58 (11.9)
Current smokers, n (%) 138 (41.7) 13 (8.9) 269 (34.3) 34 (7.0)
Weighted GRS§ 12.6 (2.0) 12.9 (2.1) 12.3 (2.1) 12.3 (2.1)
Data are expressed as mean (SD) unless otherwise indicated.
*The range of the MedDiet score is from 0 to 9, with higher values indicating greater adherence to the MedDiet.
33
†Defined as a systolic blood pressure of 140 mm Hg or higher or a diastolic blood pressure of 90 mm Hg or higher, or self-reported receipt of
an antihypertensive treatment.
‡ Identified through self-reported T2DM-specific medication use or self-reported medical diagnosis of T2DM.
§The minimum and maximum weighted GRS values were 4.6 and 18.8.
CHD, coronary heart disease; EPIC, European prospective investigation into cancer and nutrition; GRS, genetic risk score; MedDiet,
Mediterranean diet; MET, metabolic equivalent.
Table 2 ORs for CHD incidence by conventional risk factors in the Greek-EPIC cohort*
OR (95% CI) p Value
Smoking status (current vs never/former smokers) 1.39 (1.08 to 1.80) 0.012
Hypertension (yes vs no) 2.16 (1.68 to 2.78) <0.001
Type 2 diabetes mellitus (yes vs no) 3.36 (2.52 to 4.47) <0.001
Physical activity (≥sex-specific median vs <sex-specific median) 0.70 (0.56 to 0.87) 0.002
Energy intake (≥sex-specific median vs <sex-specific median) 0.75 (0.60 to 0.93) 0.011
MedDiet score (≥sex-specific median vs<sex-specific median) 0.89 (0.71 to 1.11) 0.299
Body mass index (≥25 vs <25 kg/m
2) 1.45 (1.08 to 1.96) 0.015
Waist-to-hip ratio (≥sex-specific median vs <sex-specific median) 1.46 (1.17 to 1.81) 0.001
*Association tested with unconditional logistic regression adjusted for age, sex and genetic risk score; median values according to the overall
sample (cases and controls combined).
CHD, coronary heart disease; EPIC, European prospective investigation into cancer and nutrition; MedDiet, Mediterranean diet.
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Open Accessspeciﬁed genetic risk background.
34 37 The results of the
present study indicate that persons at high genetic risk
for CHD increase this risk when they move into a high-
risk category of a conventional cardiovascular risk factor
no more than persons at low genetic risk, although they
end up with a higher overall risk on account of the joint
presence of high-risk genetic predisposition and ConvRF.
Our results are not incompatible with those of previous
investigations focusing on joint effects of genetic predis-
position, assessed in variable ways and selected ConvRFs
for CHD.
38 In this respect, Tavani et al
39 have previously
examined the joint effect of a family history of heart
disease, taken as a proxy for genetically determined pre-
disposition to the disease, and selected adult life risk
factors on the risk of the disease and have shown that a
substantial increase in heart disease is evident when a
family history and the environmental risk factors are
present.
In the present investigation, we found no evidence of
superadditive or subadditive effect of the GRS in con-
junction with several ConvRFs. This does not preclude
that such interactions does not exist between ConvRFs
that were not studied in the present investigation and
genetic variants not included in the GRS, over and
beyond issues related to statistical power.
21 40 41 It does
appear, however, that the joint effects of genetic and
non-genetic risk factors tend, generally, to be additive.
Strengths of the present nested case–control investiga-
tion are the population based prospective cohort design
of the underlying study, the minimal concern for popu-
lation stratiﬁcation and the use of single-nucleotide
polymorphisms with documented association with CHD.
In this investigation, the effect estimates for the
ConvRFs used (smoking, hypertension, etc), as well as
the genetic factors which were components of the GRS
were comparable with those reported in the literature
that argues for the validity of the database used.
10 16
Nevertheless, the use of single baseline measurements
of ConvRFs can lead to underestimation of associations
with CHD risk (through regression dilution bias).
42 For
example, the association between smoking and cardio-
vascular disease is intrinsically underestimated in cohort
studies, since a proportion of smokers stop after data
collection, and the RR falls rapidly after stopping.
Correcting for within-person variation in lifestyle factors
over time may result in more informative estimates of
CHD risk associated with these factors, particularly for
the risks associated with continued smoking and the
beneﬁts of regular physical activity,
43 and, therefore,
future studies should take these inﬂuences into
account. The main limitation of this study stems from
the modest numbers of incident CHD cases, not with-
standing the fact that the underlying cohort was large
and was followed for approximately 10 years. In add-
ition, due to lack of available data on certain conven-
tional risk factors of CHD, such as blood cholesterol
levels, we were not able to examine in this study their
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Relative Excess Risk due to
Interaction (RERI)
N OR (95% CI) N OR (95% CI) N OR (95% CI) N Estimate (95% CI) p Value
Smoking status (lower risk: never/
former smokers higher risk: current
smokers)
630 1.75 (1.22 to 2.49) 223 1.49 (1.15 to 1.92) 664 1.70 (1.19 to 2.41) 231 –0.54 (–1.31 to 0.24) 0.18
Hypertension (lower risk: no; higher
risk: yes)
318 2.07 (1.45 to 2.94) 535 1.21 (0.81 to 1.80) 305 2.72 (1.92 to 3.83) 590 0.44 (–0.27 to 1.16) 0.22
Type 2 diabetes mellitus (lower risk:
no; higher risk: yes)
740 3.72 (2.45 to 5.63) 113 1.34 (1.05 to 1.71) 765 4.13 (2.79 to 6.12) 130 0.07 (–1.94 to 2.07) 0.95
Physical activity (lower risk:
≥sex-specific median; higher risk:
<sex-specific median)
425 1.36 (0.99 to 1.88) 428 1.25 (0.92 to 1.71) 451 1.86 (1.36 to 2.54) 444 0.25 (–0.32 to 0.81) 0.39
Energy intake (lower risk:
≥sex-specific median; higher risk:
<sex-specific median)
439 1.47 (1.07 to 2.03) 414 1.43 (1.05 to 1.94) 436 1.75 (1.29 to 2.39) 459 –0.14 (–0.76 to 0.47) 0.65
MedDiet score (lower risk: ≥4.0;
higher risk: <4.0)
574 1.03 (0.73 to 1.43) 279 1.24 (0.95 to 1.60) 616 1.51 (1.10 to 2.08) 279 0.25 (–0.29 to 0.79) 0.36
Body mass index (lower risk: <25 kg/
m
2; higher risk: ≥25 kg/m
2)
143 1.56 (0.99 to 2.46) 710 1.47 (0.84 to 2.56) 152 2.01 (1.28 to 3.15) 743 –0.02 (–0.82 to 0.78) 0.96
Waist-to-hip ratio (lower risk:
<sex-specific median; higher risk:
≥sex-specific median)
433 1.40 (1.02 to 1.93) 420 1.25 (0.92 to 1.71) 439 1.88 (1.39 to 2.55) 456 0.23 (–0.35 to 0.80) 0.44
*Association tested with unconditional logistic regression adjusted for age and sex. Statistically significant results (p≤0.05) are in italic fonts.













































































































sIn conclusion, this study provides evidence that
genetic and conventional cardiovascular risk factors tend
to have additive consequences on CHD, an issue that
may be of preventive importance when genetic predis-
position could not be assessed through an ad hoc
genetic risk score but simply through a positive family
history.
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